Actively Recruiting

Phase 3
Age: 18Years - 85Years
All Genders
NCT07548385

Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN

Led by Icahn School of Medicine at Mount Sinai · Updated on 2026-04-23

235

Participants Needed

1

Research Sites

46 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, randomized study. The purpose of this study is to evaluate if the addition of Suzetrigine, a new pain medication, to well established peri-operative pain regimen used for total knee replacement surgery will effect pain control. 1. Does Suzetrigine given pre-operatively decrease the total opioid consumed after total knee replacement surgery? 2. Dose Suzetrigine given pre-operatively decrease the visual analog pain scale pain scores after total knee replacement surgery? Study participants will be randomly assigned to receive either Suzetrigine medication or placebo medication.

CONDITIONS

Official Title

Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 to 85 years old
  • Scheduled to undergo total knee replacement surgery
  • All genders
Not Eligible

You will not qualify if you...

  • American Society of Anesthesiology Physical Classification (ASA) Class V
  • Urgent or emergent surgery
  • Contraindications to Suzetrigine: taking moderate-to-severe CYP3A inhibitors (e.g., Ritonavir, Voriconazole, Clarithromycin)
  • Contraindications to Suzetrigine: taking moderate-to-severe CYP3A inducers (e.g., Phenytoin, Carbamazapine, Rifabutin)
  • Moderate to severe hepatic impairment
  • History of substance use disorder, chronic opioid use, or alcohol abuse
  • Reoperation
  • Patient refusal or inability to consent
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mount Sinai West

New York, New York, United States, 10019

Actively Recruiting

Loading map...

Research Team

M

Michael Lazar, MD

CONTACT

H

Himani Bhatt, DO

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here